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A B S T R A C T
Antidepressants are commonly employed for the treatment of major depressive disorders and other psychiatric
conditions. We investigated the relatively acute cytotoxic effects of three commonly prescribed antidepressants:
fluoxetine, sertraline, and clomipramine on rat primary blood brain barrier endothelial cells over a concentra-
tion range of 0.1–100 μM. At therapeutic concentrations (0.1 μM) no significant cytotoxicity was observed after
4, 24, or 48 h. At high therapeutic to overdose concentrations (1–100 μM), antidepressants reduced cell viability
in proportion to their concentration and exposure duration. At 1 μM, antidepressants significantly reduced mi-
tochondrial membrane potential. At drug concentrations producing ~ 50% inhibition of cell viability, all drugs
significantly reduced cellular oxygen consumption rates, activities of mitochondrial complexes I and III, and trig-
gered a significant increase of lactate production. Fluoxetine (6.5 μM) and clomipramine (5.5 μM) also signifi-
cantly lowered transcellular transport of albumin. The mechanism of cellular cytotoxicity was evaluated and at
high concentrations all drugs significantly increased the production of reactive oxygen species, and significantly
increased the activity of the pro-apoptotic caspases-3, 8, and 9. Comet assays revealed that all drugs were geno-
toxic. Pre-incubation of cells with glutathione significantly ameliorated antidepressant-induced cytotoxicity, in-
dicating the potential benefit of treatment of overdosed patients with antioxidants.
1. Introduction
Major depressive disorder (MDD) is a multifactorial disease affect-
ing an estimated 350 million people worldwide and across all ages
(WHO, 2016). Depression is the leading cause of disability and a ma-
jor contribution to the global burden of disease (Smith, 2014; WHO,
2016). Antidepressants are first-line therapeutic drugs used to treat
MDDs, and other conditions including dysthymia, anxiety disorders,
obsessive-compulsive disorder (OCD), and also to combat neuropathic
pain and migraines. Antidepressants can be loosely categorised into tri
cyclic antidepressants (TCAs); cyclic antidepressants; mixed action
agents; selective serotonin reuptake inhibitors (SSRIs); serotonin-norep-
inephrine reuptake inhibitors; monoamine oxidase inhibitors; and alter-
native (non-traditional) antidepressants (Ciraulo et al., 2004).
Many factors influence antidepressant drug selection including the
potential of pharmaco-toxicity. Patient trialling of an antidepressant
drug may require an adequate dose of drug for several weeks to prove
efficacious, and pharmacotherapy then continued for ~ 6–12 months or
indeed indefinitely for recurrently depressed patients. This raises con-
cerns of both acute and chronic drug-induced cytotoxicity.
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Over the last two decades there has been upward trend in prescrib-
ing of antidepressants in the USA and UK (Mojtabai and Olfson, 2014;
Mars et al., 2017); which for the UK was driven by an increase in pre-
scribing SSRIs such as Fluoxetine (FLX) and Sertraline (SER). FLX is now
the first choice antidepressant used to treat children and adolescents as
a monotherapy of unipolar depression, and is approved by the Food and
Drug Administration (FDA) and European Medicines Agency (EMEA)
(Masi et al., 2010; Taurines et al., 2011). SSRIs are thought to relieve de-
pression symptoms by a number of mechanisms that include increasing
serotonin (5-hydroxytryptamine) levels in the brain. SSRIs inhibit sero-
tonin reuptake transporters at presynaptic terminals and thereby sus-
tain levels of serotonergic neurotransmitter levels at post-synaptic clefts
(Benfield et al., 1986; Murdoch and McTavish, 1992; MacQueen et al.,
2001; Ciraulo et al., 2004; Perez-Caballero et al., 2014).
In contrast to SSRIs, the number of prescriptions of TCAs in the UK,
such as Clomipramine (CLM), has remained stable over the same time
course (Mars et al., 2017). TCAs mainly exert their effects via inhibi-
tion of presynaptic neural reuptake of serotonin and nor-epinephrine
(McTavish and Benfield, 1990; Ciraulo et al., 2004; Gillman, 2007). Al-
though prescribing CLM is associated with a greater benefit compared
to placebo than that seen for SSRIs for treating paediatric OCD, it is not
recommended for first-line use because of its adverse effects and limited
tolerability (Varigonda et al., 2016).
To exert their cellular effects, antidepressants need to cross the blood
brain barrier (BBB). The BBB is comprised of endothelial cells that are
associated together by tight and adherens junctions. This interlinking
of endothelial cells with little fenestration limits the ability of mol-
ecules to cross them from the blood to enter brain tissue. The base-
ment membrane of the endothelial cells (and resident pericytes) is also
in close association with foot processes of brain glial cells such as as-
trocytes. Hence the BBB provides a protective cell layer that separates
the CNS from circulatory blood and is able to regulate the uptake of
endogenous molecules and xenobiotics into the brain (Schinkel, 1999;
Abbott et al., 2010; O'Brien et al., 2012). Certain small lipophilic mol-
ecules (< 400 Da in size) are able to cross the BBB by passive diffu-
sion, whereas other (larger) molecules and certain drugs including anti-
depressants, may be uni-directionally transported from the brain across
the BBB to the blood driven by the consumption of ATP (Schinkel and
Jonker, 2003; Horstmann and Binder, 2009; O'Brien et al., 2012). These
luminal membrane energy-dependent efflux pumps include proteins of
the multidrug resistance-associated (MDR) gene family such as P-glyco-
protein (P-gp), and act to provide resistance to drug toxicity (Regina et
al., 1998; Schinkel, 1999; Schinkel and Jonker, 2003; Horstmann and
Binder, 2009; Abbott et al., 2010; O'Brien et al., 2012).
A number of established protocols exist for production of BBB cells
that use isolated monocultures of endothelial cells of primary or tumori-
genic origin, or mixed co-cultures that include glial cells such as as-
trocytes (Abbott et al., 1992; Perrière et al., 2005; Roux and Couraud,
2005; Weksler et al., 2005). The ability to culture cell lines continu-
ally provides convenience and initial reproducibility, but ultimately pro-
gressive genetic and phenotypic cell changes may arise and lead to
dedifferentiation and selection of rapidly proliferating clones. Further-
more, lab-specific culturing conditions promote culture outgrowth. Hu-
man primary cells provide physiologically relevant cells, but ethical
clearance and cost may be prohibitive to use. By contrast, although
there are limitations associated with species specific responses, labora-
tory rats provide a useful source of primary cells to model drug effects
on BBB endothelial cells.
Thus the ability to isolate and culture primary rat endothelial cells
of the BBB provides an in vitro model able to evaluate local cyto-
toxicity that could impact upon BBB integrity and functionality. The
objective of this study was to assess the cytotoxicity of two of the
widely prescribed antidepressants from the SSRIs class, FLX and SER,
and CLM from the TCAs class, to rat cerebral microvascular endothelial
cells (rCMEC), and examine the molecular mechanism of any drug-in-
duced cytotoxicity.
2. Materials and methods
2.1. Chemicals and reagents
Fluoxetine (N-methyl-3-phenyl-3-[4-(trifluoromethyl)phe-
noxy]propan-1-amine) (C⁠17H⁠18F⁠3NO; MW = 309.13 g/mol), Sertraline
(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaph-
thalen-1-amine (C⁠17H⁠17Cl⁠2N; MW = 306.23 g/mol), and Clomipramine
(3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethyl-
propan-1-amine) (C⁠19H⁠23ClN⁠2; MW = 314.85), and all other reagents
were purchased from Sigma (St. Louis, MO, USA) unless detailed other-
wise. For cell treatments, drugs were dissolved in DMSO and used
at the final concentrations specified in Figures. Cell culture reagents
were bought from Gibco BRL (Grand Island, NY, USA). Mitotracker
green was purchased from Molecular Probes (Invitrogen, Carlsbad, CA,
USA).
2.2. Animals
Male Albino rats (~ 250 g body weight) were used for this study. All
experiments were approved by the Mansoura Faculty of Medicine Ethi-
cal Committee. Rats were sacrificed under sodium pentobarbital anaes-
thesia.
2.3. Isolation and characterisation of rat cerebral microvascular endothelial
cells (rCMECs).
Isolation of rCMECs was based upon published methods (Abbott et
al., 1992; Regina et al., 1998; Perrière et al., 2005; Weksler et al.,
2005; Calabria et al., 2006; Nakagawa et al., 2009; Liu et al., 2014).
After isolation, cells were purified using a 33% continuous Percoll gra-
dient. Cells were washed and then plated on 35 mm collagen IV/fi-
bronectin-coated plates (0.1 mg/ml). Isolated cells were maintained in
Endothelial Cell Growth Medium (Sigma 211–500) supplemented with
4 μg/ml puromycin and 100 mg/ml heparin and maintained in 5% CO⁠2
at 37 °C. After 3 days, puromycin was removed from the media (Liu et
al., 2014). Primary BBB endothelial cells were of the typical elongated
spindle-like morphology (Abbott et al., 1992), and were essentially ho-
mogeneous when visualized by light microscopy (Supplementary Fig.
S1), consistent with the ~ 99% purity estimates detailed by others
(Perrière et al., 2005; Calabria et al., 2006). Under these culturing con-
ditions, BBB endothelial cells display improved barrier properties in part
mediated by increased expression of tight junction proteins (Calabria et
al., 2006). Further purity confirmation was established via expression
of the BBB endothelial cell transport proteins P-glycoprotein (P-gp) and
breast cancer resistant protein (BCRP), and the puromycin-induced ex-
pression of the tight junction proteins Zonula occludens-1 (ZO-1) and
Occludin by Western blotting. (Regina et al., 1998; Schinkel, 1999;
Abbott et al., 1992; Schinkel and Jonker, 2003; Perrière et al., 2005;
Weksler et al., 2005; Calabria et al., 2006; Horstmann and Binder, 2009;
O'Brien et al., 2012).
Cell homogenates were resolved using a 4% acrylamide/bisacry-
lamide gel, proteins transferred to a nitrocellulose membrane, and then
membranes washed and incubated in blocking buffer according to pre-
vious publications (Erdozain et al., 2014; Carter et al., 2015). Blocked
membranes were incubated with primary antibodies: anti-P-gp mon-
oclonal antibody (C219, Signet Laboratories, Dedham, MA, USA) at
1:200 dilution, anti-BCRP (Bxp-53, Enzo Life Sciences, Farmingdale,
NY, USA) at 1:5000, anti-ZO-1 rabbit polyclonal (Invitrogen) at 1:1000,
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and anti-Occludin rabbit monoclonal (Abcam) at 1:10,000, overnight
at 4 °C. Washed membranes were then incubated for 2 h at room tem-
perature with the secondary antibodies (anti-mouse IgG-HRP (Dako
Cytomatics, Glostrup, Denmark) at 1:1000 dilution or anti-rat IgG at
1:10,000 dilution (Protein Tech group, Chicago, USA), respectively)
in blocking buffer. Membranes were washed and immunoreactive pro-
teins visualized using enhanced chemiluminescence (ECL kit, Amer-
sham, Buckinghamshire, UK). Western blot images are included as Sup-
plementary Fig. S1.
2.4. Cell viability assays
Cells were seeded at 1 × 10⁠4 cells per well in 96-well plates and
grown until confluent. Cells were then incubated for 4, 24, and 48 h
in the presence of the antidepressant drugs at concentrations of 0.1, 1,
10 and 100 μM. To evaluate cell cytotoxicity, cells were incubated with
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
according to a previous publication (Elmorsy et al., 2014). MTT ab-
sorbance values were expressed as a percentage of vehicle controls (de-
fined as 100%). Each drug concentration was tested in 3 separate exper-
iments and each experiment performed in triplicate.
Alamar Blue (AB) (InVitrogen) dye binding fluorescence was also
used as a measure of cell viability (O'Brien et al., 2000; Elmorsy and
Smith, 2015). After incubation with drugs, 10 μL of AB reagent was
added per well, plates incubated for 4 h, and then the absorption read
at 590 nm using a Dyne MRX microplate reader (Dyne Technologies,
Chantilly, USA). Viability was expressed as a percentage of DMSO vehi-
cle control readings (set at 100%). Each drug concentration was tested
in 3 separate experiments and each experiment performed in triplicate.
For assays of trypan blue exclusion, cells were cultured in 24-well
plates, grown until confluent and treated with antidepressants at the
same concentrations used for MTT assays. Twenty-four hours post-treat-
ment, both the attached and floating cells were harvested, resuspended
in 1 ml phosphate buffered saline, and then 100 μl 0.4% trypan blue
added. Cell viability as trypan blue exclusion was measured using a
haemocytometer, with results expressed as percentage viability relative
to control treated cells. Experiments were repeated at least 3 times for
each drug treatment and each experiment was performed in triplicate.
Intracellular ATP levels were quantified using an ATP assay kit (Ab-
cam, Cambridge, MA, USA) according to the manufacturer's guidelines,
as detailed in Elmorsy et al. (2016). Briefly, cells were seeded at 1 × 10⁠4
cells per well in 96-well plates, and grown until confluent. Cells were
then treated with antidepressants for 24 h, lysed, and measurements
taken using a luminometer ‘TopCount’ (Perkin Elmer, Uberlingen, Ger-
many). Readings of blank wells were subtracted from sample readings.
ATP levels were expressed relative to vehicle control readings. Experi-
ments were repeated at least 3 times for each drug treatment and each
experiment was performed in triplicate.
2.5. Mitochondrial measurements
Determination of mitochondrial membrane potential (MMP), and
mitochondrial complex I and complex III activity assays were performed
according to Elmorsy et al. (2016). Cells were seeded in 24 well plates
at 3 × 10⁠4 cells/well and grown to confluence. Cells were then incu-
bated with drugs for 24 h at 0.1, 1, 10, or 100 μM for MMP assays,
and at a concentration producing 50% inhibition (IC⁠50) by AB assay
(23, 38, and 30 μM for FLX, SER, and CLM, respectively), for mito-
chondrial complex I or complex III assays. Additionally to establish a
dose and effect relationship, mitochondrial complex I and complex III
assays were also performed after exposure of cells to drugs at 10 μM for
24 h. Fluorescence measurements were taken using excitation/emission
filters of 490 ⁄ 451 nm, respectively. For MMP measurements (Δψ⁠mit),
carbonyl cyanide 4-(trifluoromethoxy)-phenylhydrazone (FCCP), a
protonophoric uncoupler of oxidative phosphorylation, was used at
10 μM as a positive control. MMP measurements were also recorded us-
ing Rhodamine-123 (Rh-123) (Sigma, R8004) dye binding. In this as-
say a reduction of the integrity of the MMP triggers a redistribution
of Rh-123 and is associated with an increase of fluorescence (Emaus
et al., 1986; Baracca et al., 2003; Daunt et al., 2005). After drug treat-
ments, cells were harvested, counted, and incubated in a modified
Hanks' solution (5.6 mM KCl, 138 mM NaCl, 4.2 mM NaHCO⁠3, 1.2 mM
NaH⁠2PO⁠4, 2.6 mM CaCl⁠2, 1.2 mM MgCl⁠2, 10 mM HEPES, pH 7.4) con-
taining Rh-123 (50 μg/ml) at 37 °C for 3 min. FCCP was added to con-
firm the functional integrity of the mitochondrial membranes. Fluores-
cence measurements were undertaken using an excitation of 480 nm
and emission of 530 nm. Fluorescence was normalised to the number of
cells present. Experiments were undertaken 5–6 times with each drug at
each concentration, with each experiment performed in triplicate.
2.6. Oxygen consumption rates
Oxygen consumption rates (OCRs) were assessed polarographically
using Clark oxygen electrodes (Rank Brothers, Saudi Arabia). Cells were
treated with drugs (AB IC⁠50 concentrations and at 10 μM) or vehicle
control for 24 h, and then harvested into modified Hanks' solution con-
taining 0.1% (w/v) BSA. Basal OCRs were recorded and after 10 min
sodium azide was added (6 mM final concentration) to inhibit further
oxygen consumption. OCRs were determined as the change of O⁠2 ten-
sion over a 5 min time-course. For the effect of sodium azide, mea-
surements were taken 60 s after addition. OCRs were normalised to
the number of cells present (Daunt et al., 2005; Elmorsy and Smith,
2015). Experiments were undertaken 5–6 times with each drug at each
concentration, with each experiment performed in triplicate.
2.7. Lactate production
Cells were seeded in 24-well plates (5 × 10⁠4 cells per well) and
grown until confluent. Cells were then treated with antidepressants at
their AB IC⁠50 concentrations and at 10 μM for 24 h. Lactate was mea-
sured in the supernatant using a lactate assay kit (Biovision, Moun-
tain View, CA, USA) according to the manufacturer's instructions. Lac-
tate production were normalised to the number of cells present and ex-
pressed as a percentage of lactate produced by vehicle control treated
cells. Experiments were performed with three replicates of each treat-
ment, and repeated at least three times.
2.8. Transcellular albumin transport
Cells were grown to confluence in 24-well inserts (area 0.6 cm⁠2;
0.4 μM, Millicell, Millipore Corporation). Cells were treated with drugs
for 48 h at concentrations of 6.5, 6.5, and 5.5 μM for FLX, SER, and
CLM, respectively (concentrations of half of their respective AB assay
IC⁠50s). Control assays were performed with wells incubated with DMSO
vehicle and media only. To assess transcellular permeability, Evans
blue (0.05 mg/ml) labelled albumin (4%) was added to media within
the inserts. After 3 h, the infranatent media within the main well was
collected and the passage of labelled albumin across the cell mono-
layer determined by measuring absorbance at 620 nm (Elmorsy et al.,
2014). Experiments were performed with three replicates of each treat-
ment, and repeated at least three times.
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2.9. Reactive oxygen species (ROS) production
Twenty-four hours post-drug treatments, a 3,7-dichlorodihydrofluo-
rescein diacetate (DCFDA) assay was used to detect the presence of ROS.
For each drug, both MTT IC⁠50 and 10 μM concentrations were used. The
assay was performed according to a previous publication (Elmorsy et
al., 2014). Cell treatment with Antimycin A (10 μM for 30 min) was
used as a positive control, while non-stained cells were used as a blank.
Cells were washed with PBS and then measured for fluorescence with
485 nm excitation and 535 nm emission wavelengths. The non-stained
cell blank values were subtracted from vehicle control (ethanol) and
drug assay values. Experiments were performed with three replicates of
each treatment, and repeated at least three times.
2.10. Measurements of apoptosis
Activity of Caspases 3, 8, and 9 were measured 4 h after drug treat-
ments, with drugs applied at their MTT IC⁠50 concentrations. Caspase ac-
tivities were determined using BD ApoAlert caspase fluorescent assay
kits (Clontech Laboratories, Palo Alto, CA, USA) according to the man-
ufacturer's protocols. Experiments were performed with three replicates
of each treatment, and repeated at least three times.
2.11. Measurements of DNA damage
Single and double-stranded DNA breaks were detected by an alka-
line Comet assay (Lee and Steinert, 2003). Cells were treated with the
drugs at their MTT IC⁠50 concentrations and also at 10 μM for 24 h. Cells
were harvested in ice-cold PBS. Comet assays were performed accord-
ing to published procedures (Singh et al., 1988; De Méo et al., 1991).
After cell lysis, samples were electrophoresed for 30 min at 300 mA and
stained with propidium iodide (1 mg/ml). Cells were imaged by fluo-
rescent microscopy at 546 nm excitation and 640 nm emission wave-
lengths. Images were analysed by Comet score IV software (Perspective
Instruments, UK). Assays were performed 4–5 times for each drug con-
centration.
2.12. Cell incubations with glutathione (GSH)
Cells were incubated with 10 μM of GSH or vehicle controls for 48 h
prior to drug treatments. Cells were then washed and incubated with
antidepressants for 24 h at their MTT IC⁠50 concentrations and also at
10 μM. MTT cell cytotoxicity assays and Comet assays were then per-
formed. All experiments were performed at least three times, with each
treatment assayed in triplicate.
2.13. Statistical analysis
Statistical analysis was performed using PRISM 5 (GraphPad Soft-
ware Inc., San Diego, CA, USA) with significance defined as p < 0.05.
For comparisons of three or more groups, a one way analysis of vari-
ance (ANOVA) test was performed with Dunnett's multiple compar-
isons post-test. For two groups a Student's t-test was used. Data points
in graphs or histograms in Figures represent means ± SDs. IC⁠50 values
were calculated using a nonlinear regression analysis (log (inhibition)
versus response (variable slope) using a least squares algorithm using
Prism. Significance is indicated in Figures as *** for p < 0.001, ** for
p < 0.01, and * for p < 0.05.
3. Results
3.1. Antidepressants are cytotoxic to rCMECs
rCMECs were isolated according to published methods (Section 2.2),
cultured in the presence of puromycin to facilitate elimination of con-
taminating cells, and then characterised by the expression of BBB en-
dothelial transport proteins, P-gp and BCRP, and puromycin-induced ex-
pression of tight junction proteins ZO-1 and Occludin (Supplementary
Fig. S1), prior to experimentation.
The antidepressants FLX, SER, and CLM were assessed for cytotox-
icity to rCMECs using MTT assays (Fig. 1A), Alamar Blue assays (Fig.
1B), and depletion of cellular ATP levels (Fig. 1C). At a concentration of
0.1 μM no significant reductions of cell viability or cellular ATP levels
were observed (Fig. 1A–C). However, cell cytotoxicity (decreased cell
viability) correlated with both higher drug concentrations (1–100 μM)
and with increased exposure duration (Supplementary Table 1). All
three antidepressants displayed similar toxicological profiles but SER
was the least potent drug (highest IC⁠50 concentration) after a 24 hour
drug exposure (Fig. 1A–C and Table 2). Twenty-four hour antidepres-
sant-induced cytotoxic effects were also independently validated via a
decreased ability of treated rCMECs to exclude trypan blue dye relative
to control cells (Supplementary Fig. S2).
3.2. Antidepressants reduce cellular bioenergetics
Antidepressants depleted cellular ATP levels in a dose-dependent
fashion (Fig. 1C). Similarly, a dose-dependent significant reduction of
mitochondrial membrane potential (MMP) was observed using direct
Mitotracker dye binding (Fig. 2A, upper panel). As an alternative mea-
sure of MMP, Rhodamine-123 dye binding was used and demonstrated
a significantly increased fluorescence (consistent with reduced MMP)
after antidepressant incubation at IC⁠50 concentrations, and for FLX a
significant increase was also observed at 10 μM (Fig. 2A, lower pan-
els). When applied at their IC⁠50 concentrations, FLX, SER, and CLM all
significantly inhibited mitochondrial complex I (MC-I) activity by 27,
13, and 19%, respectively (p = 0.0037). FLX, the most potent inhibitory
drug was also able to significantly suppress MC-I activity at 10 μM
(Fig. 2B). Mitochondrial complex III (MC-III) was significantly inhibited
(20–25%) by all three drugs at their IC⁠50 concentrations (p = 0.0006),
and also significantly reduced 13 and 15% at 10 μM concentrations of
FLX or CLM, respectively (Fig. 2C). FLX, SER, and CLM significantly re-
duced cellular oxygen consumption rates (p = 0.0006) by 64, 31, and
45%, respectively, at their IC⁠50 concentrations, but not at 10 μM (Fig.
2D). The production of cellular lactate was also significantly increased
by all drugs at their IC⁠50 concentrations (33–44%, p = 0.0018) but not
after cell dosing at 10 μM (Fig. 2E).
3.3. Antidepressants reduce transcellular transport of albumin
To assess a functional deficit of BBB endothelial cell activity, the
ability of rCMECs to transport EB-labelled albumin was quantified. An-
tidepressants were administered at high therapeutic concentrations of
6.5, 6.5, and 5.5 μM for FLX, SER, and CLM, respectively. Significantly
reduced transcellular albumin transport was observed after incubation
with FLX (21% reduction) or CLM (17% reduction) (p = 0.0059) but
not SER (Fig. 3).
3.4. Antidepressant cytotoxicity correlated with increased ROS production
To provide an insight into the molecular mechanism that drives cel-
lular cytotoxicity, a DCFDA assay was performed to assess levels of
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Fig. 1. Antidepressant cytotoxicity.rCMECs were incubated with antidepressants over a concentration range of 0.1, 1, 10, and 100 μM for 4 h, 24 h, or 48 h. Cell viability was expressed
as a percentage of vehicle control readings, with data represented as means ± SD. (1A) MTT assays at 4 h, 24 h, and 48 h. (1B) AB assays at 4 h, 24 h, and 48 h. (1C) ATP assays at 24 h.
Significant differences from controls are represented with asterisks (*** for p < 0.001,** for p < 0.01, and * for p < 0.05).
ROS. FLX, SER, and CLM all significantly increased the production of
ROS at their ~ IC⁠50 concentrations (~ 17, 10, and 12-fold change, re-
spectively, (p = 0.0016)), with the most significant increase generated
after cell treatment with FLX (Fig. 4, left panel). At 10 μM, FLX also
induced ~ 3-fold significant increase of ROS production (p = 0.0235)
(Fig. 4, right panel).
3.5. Antidepressant cytotoxicity is mediated via increased apoptosis and
DNA damage
The pro-apoptotic cellular caspases 3, 8, and 9 were all significantly
activated (1.5–2.3-fold) by each of the antidepressants (p < 0.0001,
p < 0.0001, and p = 0.0084, respectively) (Fig. 5A–C). Genotoxic ef-
fects were also assessed via quantification of Tail DNA (TD) and Tail
moment (TM). At their IC⁠50 concentrations FLX, SER, and CLM all sig-
nificantly increased TD percentage (~ 3–3.5-fold, p = 0.001) (Fig. 6A,
upper panel), and FLX also significantly increased TM percentage ~ 2.5
fold (p = 0.0011) (Fig. 6B, upper panel). At 10 μM, FLX was also still
able to significantly increase TD percentage (~ 2.2-fold, p = 0.024)
(Fig. 6A, lower panel), but no significant changes to TM percentage
were observed after dosing cells with antidepressants at 10 μM (Fig. 6B,
lower panel).
3.6. Cytotoxic protection by glutathione
Cells pre-incubated with the antioxidant GSH for 48 h prior to anti-
depressant drug treatment at IC⁠50 concentrations displayed significantly
reduced levels of cytotoxicity (p = 0.027, p = 0.005, and p = 0.028 for
FLX, SER, and CLM, respectively) (Fig. 7, upper panel). Cell cytotoxic-
ity in response to drug concentrations of 10 μM was also countered after
glutathione pre-incubations but these changes did not reach significance
(Fig. 7, lower panel).
4. Discussion
4.1. Cytotoxicity of antidepressant drugs
Our aim was to evaluate the potential cytotoxicity of antidepres-
sants to endothelial cells of the BBB. We scrutinised three antidepressant
drugs (FLX, SER, and CLM) that are widely prescribed to treat a range
of psychiatric problems including MDD. We employed a combination of
assays to provide independent and overlapping means to establish cel-
lular cytotoxicity: MTT and AB dye binding assays that display over-
lapping sensitivities for measuring cellular metabolic (reducing) activity
(O'Brien et al., 2000); ATP levels as a measure of active cellular func-
tionality; and the ability to exclude trypan blue to establish the presence
of an intact cell membrane with associated cell viability.
To provide clinical relevance to our in vitro study we assessed cy-
totoxicity across a broad concentration range. Our study was designed
to cover therapeutic, hyper-therapeutic, and also overdose concentra-
tions, and enabled us to examine the molecular mechanisms that drive
drug-induced cytotoxicity within a 24 h time-frame, and without our
results being compounded by extensive cellular proliferation. Patients
are typically prescribed FLX at a dosage of between 20 and 80 mg
per day (Benfield et al., 1986; Ciraulo et al., 2004; Gartlehner et al.,
2011). Since FLX has an elimination half-life of several days,
steady-state plasma levels of 0.2–0.3 mg/L (~ 0.6–1 μM) have been
recorded after ~ 2–4 weeks of 60 mg/day (Benfield et al., 1986). SER
is administered at a typical 50–200 mg daily dosing (Gartlehner et al.,
2011), with peak plasma concentrations of 20–55 μg/L (0.07–0.2 μM)
observed 4–8 h after dosing of 100 mg SER (Murdoch and McTavish,
1992). There is a positive correlation between oral dose of SER and
drug plasma levels ranging from ~ 14–113 ng/ml (up to ~ 0.4 μM),
with plasma levels of 25–50 ng/ml (~ 0.1–0.16 μM) adequate for clin
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Fig. 2. Antidepressants effects upon cellular bioenergetics.(A, upper panel) rCMECs were incubated with antidepressant drugs over a concentration range of 0.1, 1, 10, and 100 μM
for 24 h and mitochondrial membrane potential determined. The mitochondrial uncoupler FCCP at 10 μM was used as a positive control. (A, lower panels) rCMECs were incubated
for 24 h with antidepressant drugs at their IC⁠50 concentrations or at 10 μM and Rhodamine-123 fluorescence determined (B) Mitochondrial complex I activity was determined after a
24 h incubation with antidepressants at their IC⁠50 concentrations or at 10 μM. (C) Mitochondrial complex III activity was determined after a 24 h incubation with antidepressants at
their IC⁠50 concentrations or at 10 μM. (D) Cellular oxygen consumption rates were determined after a 24 h incubation with antidepressants at their IC⁠50 concentrations or at 10 μM. (E)
Lactate production in cell supernatants was determined after a 24 h incubation with antidepressants at their IC⁠50 concentrations or at 10 μM. 24 h IC⁠50 concentrations were used for all
experiments. Histograms are displayed relative to vehicle control values of 100%, with significant changes from controls marked with asterisks. For significance: *** for p < 0.001, ** for
p < 0.01, and * for p < 0.05.
Fig. 3. Antidepressants effects upon transcellular albumin transport.rCMECs were
incubated with antidepressants at concentrations of 6.5, 6.5, and 5.5 μM for FLX, SER, and
CLM, respectively, for 48 h. After 3 h the passage of Evans blue-labelled albumin across
the cell monolayer was determined. Transcellular albumin transport values significantly
different from controls (100%) are marked with asterisks. For significance, ** for
p < 0.01, and * for p < 0.05.
ical management (Mauri et al., 2003). CLM is usually administered
at a dose range of 50–250 mg/day, with steady-state plasma concen-
trations of ~ 100–300 μg/L (~ 0.3–1 μM) reported after 7–14 days of
100–200 mg/day (Stern et al., 1980; McTavish and Benfield, 1990).
Patients with MDD often experience suicidal ideation, with a high
risk of suicide particularly at the initial phase of treatment prior to ex-
periencing therapeutic benefit. Hence overdosing with anti-depressants
may be a chosen form of suicide (Buckley and McManus, 2002). SS-
RIs have a high therapeutic index and moderate overdoses may still
be asymptomatic and without serious sequelae, whereas adverse effects
may be evident at high overdose levels (Barbey and Roose, 1998). Rec-
ommendations suggest emergency department referral for patients that
have taken greater than five times their therapeutic dose (Nelson et
al., 2007). Patient fatality may occur at overdose, particularly when
co-ingested with other substances such as alcohol (Barbey and Roose,
1998). Details of overdose concentrations are compounded by factors
including limited reporting of patient age, time of blood sampling
post-mortem, and possible co-ingested drugs. Nevertheless, a number of
reports of plasma concentrations of overdosed patients exist: for FLX
concentrations of ~ 15–19 μM (Kincaid et al., 1990; Barbey and Roose,
1998; Schulz et al., 2012); SER from ~ 5–10 μM (Schulz et al., 2012);
and CLM from 3–6 μM (Schulz et al., 2012).
Our study demonstrated that antidepressants are cytotoxic to rCMEC
at hyper-therapeutic and overdose concentrations (1–100 μM) after
24–48 h exposures. Accumulating experimental evidence similarly sup-
ports cytotoxic and anti-proliferative effects of these antidepressants on
cells grown in culture, animal models, and human studies of drug-in-
duced liver injury (Hansson et al., 1997; Davies and Kluwe, 1998;
Carvajal García-Pando et al., 2002; Thibaut and Porte, 2008; Krishnan
et al., 2008; Li et al., 2012; Chen et al., 2014; Voican et al., 2016). Our
studies suggest that 24 h post-treatment SER is the least cytotoxic to
BBB cells of the antidepressants investigated and displayed
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Fig. 4. Production of reactive oxygen species as a response to cell treatment with antidepressants.rCMECs were incubated with antidepressant drugs at their 24 h MTT IC⁠50 concentrations
or at 10 μM for 24 h and the levels of reactive oxygen species determined using a DCFDA assay. Histograms depict mean values ± SD. Significant changes from controls are marked with
asterisks. For significance: ** for p < 0.01, and * for p < 0.05.
the highest IC⁠50 values, but by 48 h all three antidepressants were of
similar toxicity (Table 1).
4.2. Antidepressant-induced inhibition of cellular bioenergetics and
induction of apoptosis
We have demonstrated that at hyper-therapeutic concentrations an-
tidepressants are able to inhibit mitochondrial function (Fig. 2A–C) and
deplete cellular ATP levels (Fig. 1C). The proton ionophore FCCP was
used as a positive control for disruption of the MMP. FCCP, a weak li-
posoluble acid, is able to diffuse across the IMM and dissipate the pro-
ton gradient to reduce the MMP (Fig. 2A, upper panel). By contrast,
at 10 μM the antidepressants FLX, SER, and CLM were only weak in-
hibitors of MC-I or MC-III, hence amelioration of MMP was not as exten-
sive as FCCP.
The antidepressant-induced reduction of mitochondrial function and
cellular bioenergetics was evidenced by reduced cellular oxygen con-
sumption rates (Fig. 2D), and increased anaerobic metabolism and lac-
tate production (Fig. 2E). Additionally, the energy (ATP) requiring ad-
sorptive-mediated transcytosis of albumin across rCMECs (Smith and
Borchardt, 1989; Poduslo et al., 1994; Hervé et al., 2008; Abbott et al.,
2010) was also impaired (Fig. 3).
The inhibition of mitochondrial function and induction of apopto-
sis may well be one of the common mechanisms of drug-induced cy-
totoxicity including that triggered by antidepressants (Xia et al., 1998;
Levkovitz et al., 2005; Lee et al., 2009; Li et al., 2012; Hynes et
al., 2013; Mun et al., 2013; Chen et al., 2014; Elmorsy et al., 2014,
2016). Induced apoptosis may proceed via a number of extrinsic and/
or intrinsic pathways that trigger activation of a cascade of caspases
that culminate with activation of the ‘executioner’ caspase-3 (Elmore,
2007). All three antidepressants activated caspases-3, 8 and 9, indica-
tive of triggering both extrinsic and intrinsic apoptotic pathways.
4.3. Antidepressant-induced redox stress and DNA damage
The antidepressants induced cellular redox stress via an increased
production of reactive oxygen species (ROS). ROS induction was in the
order FLX > CLM > SER, a pattern we also observed for 24 h cyto-
toxicity assays. ROS are produced under normal physiological condi-
tions but also under pathological conditions such as from damage to
MC-I activity (Valsecchi et al., 2010). Primary targets of drug-induced
ROS damage are membrane lipids (producing lipid peroxidation), pro-
teins, and DNA (Deavall et al., 2012). We observed increased produc-
tion of thiobarbituric acid-reactive products as markers of lipid per-
oxidation in response to antidepressant treatment of rCMECs (our un-
published results). Mitochondria are also susceptible to ROS damage,
contributing to a disruption of the MMP, and triggering the release of
cytochrome c for induction of apoptosis (Ott et al., 2007).
The genotoxicity we observed after incubation with antidepressants
may also have been a consequence of ROS production, and/or from
the generation of other toxic cellular metabolites including antidepres-
sant radicals. In support of our results, other independent studies have
reported the induction of oxidative stress and genotoxicity after an-
tidepressant drug treatment (Post et al., 2000; Slamon et al., 2001;
Brambilla et al., 2009; Draz et al., 2009; Korobkova et al., 2012; Battal
et al., 2014). To further validate the importance of oxidative stress in
antidepressant-induced cytotoxicity, pre-incubation of cells with a rel-
atively high concentration (10 μM) of the antioxidant GSH was able to
significantly reduce their cytotoxicity. Additionally, GSH pre-incubation
was able to protect cells from antidepressant-induced DNA breakages at
antidepressant IC⁠50 concentrations (our unpublished results).
4.4. Safety concerns with the prescription of antidepressant drugs
Our studies demonstrate that 24 or 48 h after exposure to a high
therapeutic dose of 1 μM FLX, SER, or CLM, BBB cells experience di-
minished cellular bioenergetics and significant cytotoxicity. Although
other studies have reported cytotoxic effects of antidepressant drugs,
our study is the first to focus specifically on antidepressant-induced tox-
icity to rat primary microvascular endothelial cells of the BBB. Ghosh
et al. (2015) reported that human brain microvascular cells (HBMECs)
displayed mild toxicity to 5 μM SER, although the period of incubation
was for 15 min and the precise level of toxicity not quantified (Ghosh et
al., 2015).
Our study is not without limitations; there is the potential for dif-
ferential cytotoxicity to antidepressants between rat and human cells,
and monocultured cells lack the influence of glia, restricting direct ex-
trapolation to the human multi-cellular BBB. However, in vitro models
(such as ours) that assess cytotoxicity and mitochondrial dysfunction
have predictive benefit for human cytotoxicity. Indeed an assessment of
mitochondrial dysfunction when combined with cellular OCR measure-
ments has useful predictivity for high-throughput drug toxicity screen-
ing (Hynes et al., 2013).
Our mechanistic studies suggest that cytotoxicity was associated
with ROS production, genotoxicity and activation of apoptosis. The abil-
ity of glutathione to counter antidepressant-induced cytotoxicity indi-
cates the potential therapeutic benefit of co-administration of antioxi-
dants with antidepressants for patients receiving high dosage or indeed
to limit cellular damage experienced by patients that are clinically over-
dosed.
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Fig. 5. Caspase activation as a response to cell treatment with antidepressants.rCMECs
were incubated with antidepressant drugs at their 24 h MTT IC⁠50 concentrations for 4 h
and then activity of caspase-3 (A), caspase-8 (B), and caspase-9 (C) determined relative to
vehicle controls. Histograms depict mean values ± SD. Significant changes from controls
are marked with asterisks. For significance: *** for p < 0.001, ** for p < 0.01, and * for
p < 0.05.
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Fig. 6. DNA damage as a response to cell treatment with antidepressants.rCMECs were incubated with antidepressant drugs at their 24 h IC⁠50 concentrations (6A, 6B, upper panels) or at
10 μM (6A, 6B, lower panels) for 24 h and the production of DNA breaks determined by alkaline Comet assays. The Tail parameters: Tail DNA (TD) and Tail moment (TM) were quantified
in antidepressant treated cells and vehicle controls. Histograms depict mean values ± SD. Significant changes from controls are marked with asterisks. For significance: ** for p < 0.01,
and * for p < 0.05.
Fig. 7. The effect of the antioxidant glutathione on antidepressant-induced cytotoxic-
ity.rCMECs were pre-incubated with glutathione for 48 h, after which cells were treated
for 24 h with antidepressant drugs at their 24 h MTT IC⁠50 concentrations or at 10 μM. A
MTT assay for cell cytotoxicity was then performed. Histograms depict mean values ± SD.
Significant changes from controls are marked with asterisks. For significance: ** for
p < 0.01, and * for p < 0.05.
9
UN
CO
RR
EC
TE
D
PR
OO
F
E. Elmorsy et al. Toxicology in Vitro xxx (2017) xxx-xxx
Table 1
Antidepressant cytotoxicity evaluated using MTT, AB, and ATP assays.Cell viability was determined across an antidepressant concentration range of 0.1–100 μM. IC⁠50s were estimated
using non-linear regression from the line of best fit data with 95% confidence intervals, as detailed in previous publications (Elmorsy et al., 2014, 2016; Elmorsy and Smith, 2015). An
extrapolation of the non-linear regression was required to generate IC⁠50 values for 4 h time points.
Assay IC⁠50 concentration (μM)
4 h 24 h 48 h
FLX SER CLM FLX SER CLM FLX SER CLM
MTT 179 149 108 95 141 113 14 15 14
AB 104 115 99 23 38 30 13 13 11
ATP ND ND ND 12 15 13 ND ND ND
Drug structures Fluoxetine (FLX) Sertraline (SER) Clomipramine (CLM)
Footnote: ND = not determined.
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